New Delhi: Drug firm Lupin has launched in the US market the generic version of Celebrex capsules used for the treatment of osteoarthritis, rheumatoid arthritis and acute pain.
Its US subsidiary, Lupin Pharmaceuticals Inc, has launched the authorised generic for GD Searle LLC's (a subsidiary of Pfizer) Celebrex capsules of strength of 50 mg, 100 mg, 200 mg and 400 mg, the company said in a statement today.
Lupin had earlier signed a licensing agreement with Pfizer Inc for Celebrex, which has annual sales of $2.54 billion in the US market, it added.
The company is a significant player in cardiovascular, diabetology, asthma, paediatric, CNS, GI, anti-infective and NSAID space and holds global leadership positions in the anti-TB and Cephalosporin segment.
Lupin is the fifth largest and fastest growing top five generics player in the US and the third largest Indian pharmaceutical company by sales.
